Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Swiss Exchange  >  Novartis AG    NOVN   CH0012005267

NOVARTIS AG

(NOVN)
  Report
Delayed Quote. Delayed Swiss Exchange - 01/20 08:29:25 am
86.28 CHF   +0.89%
05:59aNOVARTIS AG : Credit Suisse reiterates its Neutral rating
MD
02:51aNOVARTIS AG : Jefferies keeps its Buy rating
MD
01/19NOVARTIS AG : JP Morgan reaffirms its Sell rating
MD
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • For a short-term investment strategy, the company has poor fundamentals.
Strengths
  • The group's high margin levels account for strong profits.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
  • The group usually releases earnings worse than estimated.
  • The company's enterprise value to sales, at 4.35 times its current sales, is high.
  • For the last four months, EPS estimates made by Standard & Poor's analysts have been revised downwards.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
NOVARTIS AG2.24%218 823
JOHNSON & JOHNSON3.43%428 525
ROCHE HOLDING AG2.98%307 190
MERCK & CO., INC.1.70%210 474
PFIZER INC.-0.22%204 160
ABBVIE INC.4.69%198 051
ELI LILLY AND COMPANY17.56%179 938
NOVO NORDISK A/S5.19%168 976
BRISTOL-MYERS SQUIBB COMPAN..7.59%150 816
AMGEN INC.7.98%144 535
ASTRAZENECA PLC5.43%138 018
SANOFI5.76%126 749
GLAXOSMITHKLINE PLC5.10%95 833
CHUGAI PHARMACEUTICAL CO., ..4.71%91 171
JIANGSU HENGRUI MEDICINE CO..-5.84%86 009
DAIICHI SANKYO COMPANY, LIM..6.08%69 805
More Results
Financials (USD)
Sales 2020 49 153 M - -
Net income 2020 8 211 M - -
Net Debt 2020 19 211 M - -
P/E ratio 2020 26,2x
Yield 2020 3,28%
Capitalization 219 B 219 B -
EV / Sales 2020 4,85x
EV / Sales 2021 4,44x
Nbr of Employees 110 000
Free-Float 86,4%
Upcoming event on NOVARTIS AG
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio
Potential
Yield
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes